These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 19615492

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC.
    Br Med Bull; 2009; 90():71-84. PubMed ID: 19474056
    [Abstract] [Full Text] [Related]

  • 4. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N, Bhargava B.
    Am J Cardiovasc Drugs; 2011; 11(1):1-12. PubMed ID: 21090826
    [Abstract] [Full Text] [Related]

  • 5. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K, Ferrari R, Tendera M, Steg PG, Ford I, BEAUTIFUL Steering Committee.
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
    Fox K, Komajda M, Ford I, Robertson M, Böhm M, Borer JS, Steg PG, Tavazzi L, Tendera M, Ferrari R, Swedberg K.
    Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E, Lerebours G, Vilaine JP.
    Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Heart rate control in an unselected consecutive population of outpatients with stable coronary artery disease: Analysis of the CARDIf Study Cohort.
    Vitale C, Iellamo F, Volterrani M, Lombardi M, Fini M, Banach M, Rosano GM.
    Angiology; 2010 Nov; 61(8):763-7. PubMed ID: 20462892
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM.
    Am J Cardiovasc Drugs; 2012 Dec 01; 12(6):415-26. PubMed ID: 23181944
    [Abstract] [Full Text] [Related]

  • 20. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
    Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL Investigators.
    Eur Heart J; 2009 Oct 01; 30(19):2337-45. PubMed ID: 19720635
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.